학술논문
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYResearch in context
Document Type
article
Author
Thomas Chatzikonstantinou; Lydia Scarfò; Georgios Karakatsoulis; Eva Minga; Dimitra Chamou; Gloria Iacoboni; Jana Kotaskova; Christos Demosthenous; Lukas Smolej; Stephen Mulligan; Miguel Alcoceba; Salem Al-Shemari; Thérèse Aurran-Schleinitz; Francesca Bacchiarri; Mar Bellido; Fontanet Bijou; Anne Calleja; Angeles Medina; Mehreen Ali Khan; Ramona Cassin; Sofia Chatzileontiadou; Rosa Collado; Amy Christian; Zadie Davis; Maria Dimou; David Donaldson; Gimena Dos Santos; Barbara Dreta; Maria Efstathopoulou; Shaimaa El-Ashwah; Alicia Enrico; Alberto Fresa; Sara Galimberti; Andrea Galitzia; Rocío García-Serra; Eva Gimeno; Isabel González-Gascón-y-Marín; Alessandro Gozzetti; Valerio Guarente; Romain Guieze; Ajay Gogia; Ritu Gupta; Sean Harrop; Eleftheria Hatzimichael; Yair Herishanu; José-Ángel Hernández-Rivas; Luca Inchiappa; Ozren Jaksic; Susanne Janssen; Elżbieta Kalicińska; Laribi Kamel; Volkan Karakus; Arnon P. Kater; Bonnie Kho; Maria Kislova; Eliana Konstantinou; Maya Koren-Michowitz; Ioannis Kotsianidis; Robert J. Kreitman; Jorge Labrador; Deepesh Lad; Mark-David Levin; Ilana Levy; Thomas Longval; Alberto Lopez-Garcia; Juan Marquet; Lucia Martin-Rodríguez; Marc Maynadié; Stanislava Maslejova; Carlota Mayor-Bastida; Biljana Mihaljevic; Ivana Milosevic; Fatima Miras; Riccardo Moia; Marta Morawska; Roberta Murru; Uttam Kumar Nath; Almudena Navarro-Bailón; Ana C. Oliveira; Jacopo Olivieri; David Oscier; Irina Panovska-Stavridis; Maria Papaioannou; Tomas Papajík; Zuzana Kubova; Punyarat Phumphukhieo; Cheyenne Pierie; Anna Puiggros; Lata Rani; Gianluigi Reda; Gian Matteo Rigolin; Rosa Ruchlemer; Marcos Daniel de Deus Santos; Mattia Schipani; Annett Schiwitza; Yandong Shen; Martin Simkovic; Svetlana Smirnova; Dina Sameh Abdelrahman Soliman; Martin Spacek; Tamar Tadmor; Kristina Tomic; Eric Tse; Theodoros Vassilakopoulos; Andrea Visentin; Candida Vitale; Julia von Tresckow; George Vrachiolias; Vojin Vukovic; Renata Walewska; Ewa Wasik-Szczepanek; Zhenshu Xu; Munci Yagci; Lucrecia Yañez; Mohamed Yassin; Jana Zuchnicka; Maria Angelopoulou; Darko Antic; Bella Biderman; Mark Catherwood; Rainer Claus; Marta Coscia; Antonio Cuneo; Fatih Demirkan; Blanca Espinet; Gianluca Gaidano; Olga B. Kalashnikova; Luca Laurenti; Eugene Nikitin; Gerassimos A. Pangalis; Panagiotis Panagiotidis; Viola Maria Popov; Sarka Pospisilova; Paolo Sportoletti; Niki Stavroyianni; Constantine Tam; Livio Trentin; Anastasia Chatzidimitriou; Francesc Bosch; Michael Doubek; Paolo Ghia; Kostas Stamatopoulos
Source
EClinicalMedicine, Vol 65, Iss , Pp 102307- (2023)
Subject
Language
English
ISSN
2589-5370
Abstract
Summary: Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. Methods: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. Findings: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p